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Brain food for babies
How does a mother supply a key building block of the brain required for neurodevelopment to 
her fetus in pregnancy? The critical requirement of docosahexaenoic acid (DHA) for fetal brain 
development, and the poor efficiency of its synthesis in humans, is a tricky metabolic problem to 
be overcome in pregnant women. Supplying this unique fatty acid to the fetus requires exquisite 
specificity and timing, processes that can unravel in disease conditions such as pre-eclampsia.
The physiological adaptation to pregnancy 
involves large increases in maternal plasma 
triglycerides: triglycerides are the storage form of 
fatty acids. We and others have shown that from the 
end of the first trimester until term there is a steady 
increase in maternal red blood cell and plasma DHA 
content of about 26%, which falls below trimester 
one concentrations after delivery5. This maternal 
mobilization may provide sufficient DHA for the 
rapid growth phase of the fetus. It has not yet been 
determined where this DHA comes from. Potential 
sources include maternal dietary intake, release 
from maternal adipose tissue and membrane stores 
or increased maternal liver synthesis, but there are 
no data that confirm whether one or more of these 
sources are important.
Studying the earliest changes in pregnancy
As mentioned above, some of the key events in 
neurodevelopment occur very early in the first 
trimester. The studies just described have only looked 
at time points that are conveniently sampled, i.e. end of 
the first trimester and beyond. Most women book for 
antenatal care between 9 and 13 weeks of gestation and 
it is very difficult to sample at earlier time points in a 
free-living population. Indeed, during the very earliest 
week of pregnancy many women are not aware that they 
are pregnant. We know from our longitudinal studies 
that red blood cell DHA content is already 19% higher 
at the end of the first trimester than it is after delivery, 
suggesting that DHA mobilization may be occurring 
prior to this time point5. In order to study these 
earliest changes we turned to a population of women 
undergoing assisted conception where accurately 
timed samples could be taken immediately before, and 
in the weeks after, conception. Women undergoing 
frozen embryo transfer, but who also retained their 
natural menstrual cycle were recruited so that we could 
avoid the potential metabolic interference of the high 
concentrations of reproductive hormones used for 
artificially reconstructing menstrual cycles in those 
women who have none.
Long chain polyunsaturated fatty acids (LC 
PUFA), particularly docosahexaenoic acid (DHA, 
22:6 n-3), have been shown in population and 
intervention studies to be extremely important 
for neurodevelopment, learning and cognitive 
function. DHA comprises a high proportion of 
brain fatty acids, mainly found incorporated in 
brain membranes, and has particular structural 
properties that enhance membrane fluidity1. DHA 
has been shown to promote neurone survival and is 
required for neurone connectivity in the brain. In 
cases of DHA deficiency, another LC PUFA, omega-6 
docosapentaenoic acid (n-6 DPA, 22:5n-6), appears 
to substitute for DHA in brain membranes. DHA is 
a LC PUFA of the n-3 series synthesized from an n-3 
fatty acid precursor molecule obtained from the diet. 
The enzymes that synthesize the n-3 LC PUFA are 
shared with the n-6 series LC PUFA derived from an 
n-6 precursor in the diet. Given that human dietary 
n-6 precursor intake is up to eight-fold higher than 
dietary n-3 precursor intake2, this means that the n-6 
pathway predominates and in humans the synthesis 
of n-3 LC PUFA is rather slow. The production of 
DHA is however higher in women than in men3.
Metabolic adaptations in pregnancy
The first brain cells are formed by day 15 of gestation; 
at 22 days the primitive brain is developing and the 
first nerves with their extending fibres are observable. 
By 28 days of gestation, closure of the neural tube 
(the precursor to the central nervous system) occurs 
and the head of the embryo grows fastest over the 
earliest gestational weeks. Thus it is evident that a 
ready supply of DHA will be required by the embryo 
very early in gestation. Tracer experiments show 
transfer of DHA via the placenta resulting in fetal 
plasma that is enriched in DHA when compared with 
their mother4. These data show that the placenta 
is capable of selectively transferring DHA from 
maternal plasma to fetal plasma and a number of 
transport processes with selectivity for DHA have 
been described.
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In this population we observed that maternal 
plasma DHA concentrations started to rise at day 
18 of pregnancy with the greatest rate of increase 
between day 18 and day 29, exactly the time of the 
earliest neurodevelopmental events including neural 
tube closure6. Furthermore, we observed that DHA 
concentrations were higher in twin compared with 
singleton pregnancies. As we had measured a full 
fatty acid profile in the samples we could also see that 
omega-6 DPA (the ‘back-up’ brain fatty acid) was also 
much higher in the women with twin pregnancies. 
It is impossible to directly measure tissue activities 
of the enzymes involved in LC PUFA synthesis in 
pregnant women; however, product precursor ratios 
are often used to infer particular enzyme activities 
in the pathway. Using this substitute measure for 
Δ6-desaturase (a key enzyme in the DHA synthetic 
pathway), a strong correlation between Δ6-desaturase 
activity and the rate of change of DHA concentration 
at day 29 of pregnancy was observed, suggesting that 
maternal DHA synthesis may indeed be switched on 
in early gestation. It was also seen that plasma levels of 
the precursor of the n-6 pathway decreased markedly 
over the first 45 days of pregnancy, which would 
reduce the competition between the parallel n-6 and 
n-3 series pathways and allow the n-3 pathway to 
proceed at a greater rate.
Pre-eclampsia – when pregnancy lipid 
metabolism goes awry 
Pre-eclampsia is a disease of pregnancy that only 
occurs naturally in humans and higher apes, 
although animal models for the disorder have been 
created. While the number of maternal deaths 
resulting from pre-eclampsia are in decline, at least 
in the developed world, the disease still results in 
many prematurely delivered infants. The primary 
defect in pre-eclampsia is located at the placenta 
with inadequate or compromised formation of the 
blood supply to the placenta. The defective placental 
function is associated with a maternal response of 
widespread endothelial dysfunction which results in 
the clinical features of water retention, protein in the 
urine and hypertension. The only real cure for the 
disease is to deliver the placenta and child, hence the 
high rates of prematurity. Pre-eclampsia is a rather 
mysterious disease and the disease pathways are not 
well understood (see  feature by Eric George on p22). 
The ability to understand pre-eclampsia is not helped 
by the variety of presentations of the disease (early 
or late presentation, mild or severe disease) and the 
variety of risk factors (first pregnancy, maternal 
obesity, etc.). The maternal metabolic adaptation 
to pregnancy also goes awry in pre-eclampsia 
and, amongst other changes, there are exaggerated 
increases in plasma triglycerides7.
We were interested to find out how disturbed 
triglyceride metabolism in pre-eclampsia might 
affect DHA metabolism and found that, in pre-
eclampsia, the third trimester maternal DHA levels 
were 40% lower than normal pregnancy levels and 
fetal plasma levels only a little better at 35% lower 
than normal8. In maternal adipose tissue in women 
delivered by Caesarean section, we found that 
expression of enzymes involved in the synthesis 
of LC PUFA in pre-eclampsia was less than half of 
that in control tissues, suggesting that maternal LC 
PUFA synthesis may be inhibited in pre-eclampsia. 
LC PUFA synthesis is also inhibited in non-alcoholic 
fatty liver disease where high amounts of fat are 
deposited in the liver. We wondered whether the 
same thing might be happening in pregnant women 
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with pre-eclampsia. In the absence of being able to 
sample maternal liver, we looked at the key organ 
involved in the transfer of DHA to the fetus, the 
placenta itself. A detailed comparison of all the fats 
in healthy and pre-eclampsia placenta demonstrated 
that placenta from women with pre-eclampsia did 
indeed have significantly higher levels of stored fat9.
Parallels with type 2 diabetes
The characteristics of poor fat handling we 
observed in pre-eclampsia, or at least that subset 
of pre-eclampsia with maternal obesity as a risk 
factor, made us think of the parallels with type 2 
diabetes. Our current understanding of the disease 
process in type 2 diabetes involves the failure of 
subcutaneous adipose tissue cells to expand and 
hence safely store excessive fatty acids as lipid 
droplets resulting in fat accumulation in tissues 
such as the liver. Therefore we looked more closely 
at adipose tissue in pre-eclampsia and found that 
there was a higher proportion of smaller adipose 
cells in women with pre-eclampsia compared with 
healthy women suggesting a reduced ability of these 
cells to expand and store fat10. Functional studies of 
adipose tissue cells in the laboratory also confirmed 
that pre-eclampsia adipose tissue released more fatty 
acids than that from healthy pregnant women. Thus 
it is possible that a similar disease process to that 
observed in type 2 diabetes is occurring in obese 
women who develop pre-eclampsia in pregnancy.
A study picture of one of our pregnant study participants 
undergoing indirect calorimetry
Gas Chromatogram of extracted erythrocyte fatty acids showing the main peaks. Docosahexaenoic acid (DHA) is the last peak 
(at 18.5 minutes) of the chromatogram.
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Where next?
We are only a part way down the road of 
understanding how  DHA is mobilized in pregnancy 
by the mother, transferred to her baby and how 
this might be disrupted in pre-eclampsia. Further 
interrogation of our database on the detailed fat 
composition of placenta will tell us about LC PUFA 
levels and composition in healthy and pre-eclampsia 
placenta. We are currently undertaking studies to 
look specifically at particles secreted by the liver 
that carry fats in maternal plasma (very low density 
lipoprotein) both in very early and later gestation 
in order to get a window into the fat composition 
of the maternal liver. Very little is understood about 
how DHA is preferentially transported across the 
placenta and in what form. What we do know is that 
DHA is an extremely important nutrient for the fetus 
and that transport processes in pregnancy appear 
to be exquisitely geared towards the early maternal 
mobilization of DHA. As the fetus can only acquire 
this important building block for the synthesis and 
development of brain tissue from the mother and our 
data demonstrate that the mother mobilizes DHA 
just prior to neural tube closure, this suggests that 
DHA supplementation (commonly taken as fish oil 
capsules) around the time of conception and in early 
pregnancy has the potential to be as important as 
folate supplementation over the same time period.  ■
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